Latest news with #Vaccines
Business Wire
5 days ago
- Health
- Business Wire
Intradermal Vaccination over Intramuscular Standard of Care
GOLDEN, Colo.--(BUSINESS WIRE)-- PharmaJet ®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that Vaccines has published the results of an implementation research study entitled Evaluating the impact of needle-free delivery of inactivated polio vaccine on Nigeria's routine immunization program: An implementation hybrid trial. 1 The study, funded by a multi-year, US$1.5 million grant from the USAID Development Innovation Ventures Program, in collaboration with the Nigeria National Primary Health Care Development Agency (NPHCDA), Jhpiego, PATH, Sydani Group and Johns Hopkins Bloomberg School of Public Health, aimed to comparatively evaluate the vaccine coverage, cost, feasibility and acceptability of using Tropis ID for fIPV delivery compared to the SoC in a routine immunization program. A household survey was completed in Kano and Oyo States following a six-month implementation with children aged 3 to 12 months. "This study demonstrates that Tropis ID can improve the patient and caregiver experience over the standard of care for routine immunizations, resulting in increased vaccine compliance, which is an important element in eradicating polio." Share This study is the first to measure coverage benefits of Tropis ID in RI settings, adding to the evidence of the value of needle-free intradermal delivery in the global pursuit of polio eradication. While Nigeria improved full regimen coverage from 33% in 2016 to 57% in 2022, 2 it is actively pursuing new approaches that may bring further improvements to coverage and reduce costs as the country prepares for transition from Gavi support, 3 while navigating funding reductions in global health programs. Tropis ID, a WHO pre-qualified needle-free delivery system, is an easy-to-use, precise, intradermal delivery method that has already been successfully used in campaign and house-to-house settings in high-risk polio environments, with over 12 million injections administered to date. 4 The Vaccines publication highlighted that when compared to the SoC, Tropis ID demonstrated: Increased coverage: IPV2 coverage was 11.2% higher. On a relative basis, this means the odds of receiving 2 doses of IPV are doubled when Tropis ID is used. Cost savings: Up to 47% total immunization costs savings can be realized when using Tropis ID for IPV delivery, 4 which equates to a potential savings for the Nigeria immunization program of ~US$50 million over a 5-year period. Acceptability: 97% of healthcare workers preferred Tropis ID for routine immunization, noting it is easy to operate, associated with less perceived discomfort by children during administration, and elicited a positive caregiver response. 'This study demonstrates that Tropis ID can improve the patient and caregiver experience over the standard of care for routine immunizations, resulting in increased vaccine compliance, which is an important element in eradicating polio,' said Paul LaBarre, Vice President Global Business Development, PharmaJet. 'With the added benefits of intradermal dose sparing and the associated cost savings, Tropis ID is an ideal immunization tool. We look forward to collaborating with other African partners to assess the benefits needle-free ID delivery can provide for their immunization programs.' Refer to Instructions for Use to ensure safe injections and to review risks. 1 Mohan, D et al, Evaluating the impact of needle-free delivery of inactivated polio vaccine on Nigeria's routine immunization program: An implementation hybrid trial, Vaccines,16 May 2025, 13(5), p.533 2 2023: A Critical Year for polio eradication efforts in northern Nigeria. Global Polio Eradication Initiative. 2023. (accessed on 21 March 2025) 3 Presentation of Evidence by the Polio Disease Working Group. Presented at the meeting of the Nigerian Immunization Technical Advisory Group, Abuja, Nigeria, 24 July 2018. 4 Data on file About PharmaJet The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. Tropis ® ID has CE Mark and WHO PQS certification for intradermal injections and is commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet visit or contact PharmaJet here. Follow us on LinkedIn. In 1988, the Global Polio Eradication Initiative (GPEI) was launched after a resolution passed by the World Health Assembly, with over 350,000 children recorded as having paralytic polio across 125 countries. The GPEI's goals are to detect and stop the spread of poliovirus and strengthen immunization programs globally. Post-eradication strategies, such as sustaining high vaccination rates and strengthening surveillance efforts, are important in the goal of eradicating polio. The GPEI Polio Eradication Strategy 2022–2026 set 2023 as a target year to interrupt all remaining type 1 wild poliovirus (WPV1) transmission (Goal One) and type 2 circulating vaccine-derived poliovirus (cVDPV) transmission (Goal Two), with the aim of reaching eradication by 2026.
Yahoo
5 days ago
- Health
- Yahoo
Publication in Vaccines Highlights Important Benefits of PharmaJet® Tropis® Intradermal Vaccination over Intramuscular Standard of Care
Substantial Improvements in Coverage of IPV2. Vaccine coverage of the second dose of inactivated polio vaccine (IPV2) administered with Tropis ID increased by 11.2% compared to the standard of care (SoC, full dose delivered by needle and syringe intramuscular delivery). On a relative basis, the odds of receiving 2 doses of IPV are doubled when using Tropis ID. Preferred by Vast Majority of Healthcare Workers. Needle-free Tropis ID was the preferred method of vaccination for routine immunization (RI) as reported by 97% of healthcare workers surveyed, who cited that, compared to the SoC, Tropis ID was (i) easier to use (95%), and (ii) children experienced less discomfort (94%). Significant Cost Reductions. Incremental savings with needle-free could range from US$0.07 to US$1.00 per dose, with up to 47% total immunization cost savings compared to the SoC in a full-scale scenario. This equates to a potential savings of ~US$50 million over a 5-year period using Tropis ID for the Nigeria immunization program. GOLDEN, Colo., June 05, 2025--(BUSINESS WIRE)--PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that Vaccines has published the results of an implementation research study entitled Evaluating the impact of needle-free delivery of inactivated polio vaccine on Nigeria's routine immunization program: An implementation hybrid trial.1 The study, funded by a multi-year, US$1.5 million grant from the USAID Development Innovation Ventures Program, in collaboration with the Nigeria National Primary Health Care Development Agency (NPHCDA), Jhpiego, PATH, Sydani Group and Johns Hopkins Bloomberg School of Public Health, aimed to comparatively evaluate the vaccine coverage, cost, feasibility and acceptability of using Tropis ID for fIPV delivery compared to the SoC in a routine immunization program. A household survey was completed in Kano and Oyo States following a six-month implementation with children aged 3 to 12 months. This study is the first to measure coverage benefits of Tropis ID in RI settings, adding to the evidence of the value of needle-free intradermal delivery in the global pursuit of polio eradication. While Nigeria improved full regimen coverage from 33% in 2016 to 57% in 2022,2 it is actively pursuing new approaches that may bring further improvements to coverage and reduce costs as the country prepares for transition from Gavi support,3 while navigating funding reductions in global health programs. Tropis ID, a WHO pre-qualified needle-free delivery system, is an easy-to-use, precise, intradermal delivery method that has already been successfully used in campaign and house-to-house settings in high-risk polio environments, with over 12 million injections administered to date.4 The Vaccines publication highlighted that when compared to the SoC, Tropis ID demonstrated: Increased coverage: IPV2 coverage was 11.2% higher. On a relative basis, this means the odds of receiving 2 doses of IPV are doubled when Tropis ID is used. Cost savings: Up to 47% total immunization costs savings can be realized when using Tropis ID for IPV delivery,4 which equates to a potential savings for the Nigeria immunization program of ~US$50 million over a 5-year period. Acceptability: 97% of healthcare workers preferred Tropis ID for routine immunization, noting it is easy to operate, associated with less perceived discomfort by children during administration, and elicited a positive caregiver response. "This study demonstrates that Tropis ID can improve the patient and caregiver experience over the standard of care for routine immunizations, resulting in increased vaccine compliance, which is an important element in eradicating polio," said Paul LaBarre, Vice President Global Business Development, PharmaJet. "With the added benefits of intradermal dose sparing and the associated cost savings, Tropis ID is an ideal immunization tool. We look forward to collaborating with other African partners to assess the benefits needle-free ID delivery can provide for their immunization programs." Refer to Instructions for Use to ensure safe injections and to review risks. 1 Mohan, D et al, Evaluating the impact of needle-free delivery of inactivated polio vaccine on Nigeria's routine immunization program: An implementation hybrid trial , Vaccines,16 May 2025, 13(5), p.5332 2023: A Critical Year for polio eradication efforts in northern Nigeria. Global Polio Eradication Initiative. 2023. (accessed on 21 March 2025)3 Presentation of Evidence by the Polio Disease Working Group. Presented at the meeting of the Nigerian Immunization Technical Advisory Group, Abuja, Nigeria, 24 July 2018.4 Data on file About PharmaJet The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. Tropis® ID has CE Mark and WHO PQS certification for intradermal injections and is commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet visit or contact PharmaJet here. Follow us on LinkedIn. About The Global Polio Eradication Strategy (GPEI) In 1988, the Global Polio Eradication Initiative (GPEI) was launched after a resolution passed by the World Health Assembly, with over 350,000 children recorded as having paralytic polio across 125 countries. The GPEI's goals are to detect and stop the spread of poliovirus and strengthen immunization programs globally. Post-eradication strategies, such as sustaining high vaccination rates and strengthening surveillance efforts, are important in the goal of eradicating polio. The GPEI Polio Eradication Strategy 2022–2026 set 2023 as a target year to interrupt all remaining type 1 wild poliovirus (WPV1) transmission (Goal One) and type 2 circulating vaccine-derived poliovirus (cVDPV) transmission (Goal Two), with the aim of reaching eradication by 2026. View source version on Contacts Nancy 1-888-900-4321 Option 3 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Times
11-05-2025
- Health
- New York Times
Trump Is Reaching Into Parents' Lives. Can Democrats Capitalize?
The prices of strollers and car seats are skyrocketing as companies race to adjust to President Trump's tariff policies. Federal support for a major campaign to promote safe infant sleep habits appears to have been cut. Measles outbreaks are terrifying parents of young children, even as the nation's health secretary undermines vaccines. The Trump administration's policies are reaching ever deeper into the lives of American families, transforming routine and apolitical parts of some parents' days — trips to the pediatrician, conversations at swim classes, chatter on online baby gear forums — into scenes of anxiety and anger. For a Democratic Party still searching for its strongest message amid the upheavals of the second Trump term, the politics of parenting offer a telling test case: Can Democrats persuade voters that this White House is making their lives harder? 'I've never heard this level of fear,' said former Representative Colin Allred, a Texas Democrat mulling a second Senate bid in his state, which has a significant measles outbreak. He said his nonpolitical friends — people who 'just want to send their kids to school and watch the Cowboys play' — were 'calling me and asking, like, 'What the hell is going on?' There are no greater motivators in politics than anger and fear. But in recent years, Republicans have been far more successful than Democrats at tapping into parents' raw emotions. In 2021, they rode waves of concern about pandemic-era education to victory in the Virginia governor's race. Last year, Democrats were caught off guard as Robert F. Kennedy Jr., the leader of the 'Make America Healthy Again' movement and now the health secretary, helped Mr. Trump win over parents worried about food additives and swayed by false information on vaccines. And while Joseph R. Biden Jr. won parents with children under the age of 18 in 2020, Mr. Trump captured that demographic in November, exit polls showed. Many Republicans have declared that they are the 'party of parents.' So far, the Democratic response has been scattershot, and there is little evidence of an organized anti-MAHA movement. But interviews with nearly 40 parents, politicians and pediatricians suggest that there is an opening for candidates who can channel parents' fury and fears — if they can connect with those voters. Trinity Chisholm, 23, a nursing student and a Democrat who was at the library last week with her 1-year-old in Chester, Va., outside Richmond, said that she was worried about measles outbreaks — and that the administration's vaccine approach was 'not based in science.' 'It just feels like it's preying on parents' insecurities and fears,' she said. State Senator Nabilah Islam Parkes of Georgia, a Democrat who has a baby, said that in Facebook parent groups, 'people are legitimately freaking out.' When 'you are shutting down safe-to-sleep campaigns, and you are undermining the trust in our vaccination programs, this is a cause for grave concern,' she said. 'These are issues that will 100 percent motivate people.' 'This is a slippery slope' As the nation confronts one of the worst measles outbreaks in a generation, Representative Brittany Pettersen, a Colorado Democrat who gave birth in January, is making the same calculations as many other parents of infants: how to protect babies who are too young for a measles vaccine. 'I'm hopeful that parents will start mobilizing, and moms are going to start mobilizing, because it's very scary,' she said. She suggested it was 'unfathomable' that someone like Mr. Kennedy could be guiding public health policy. Certainly, the large outbreak in the Southwest began in a Mennonite community, where there has long been skepticism of the medical system. And Mr. Kennedy, who has spent years spreading doubts about vaccines, has said recently that inoculations are the best way to avoid spreading measles. But he has also downplayed the seriousness of measles infections, promoted unproven treatments that may be making children more sick and taken many other actions that experts see as dangerously damaging to public confidence in vaccines, like encouraging parents to 'do your own research' before vaccinating their infants. As six of her seven children romped around a playground in Warrington, Pa., Katrina Britton, 39, who does not inoculate her kids, said that recommendation resonated. 'Vaccinations should definitely be a personal choice that every parent is educated about,' she said, praising Mr. Kennedy's efforts to curtail food dyes and seed oils and to encourage parents to make their own determinations on vaccinations. To many in the scientific and medical communities as well as his Democratic critics, Mr. Kennedy is sowing doubt about lifesaving preventative medicine. 'The culpability is on the president who nominated R.F.K. Jr., it's on R.F.K. Jr. himself, and it is on every single senator who voted to confirm,' said Representative Kim Schrier, a Washington Democrat and a pediatrician, calling Mr. Kennedy 'anti-science' and 'anti-vaccine.' Mr. Kennedy, who has promoted debunked claims about ties between vaccines and autism, has also stoked privacy concerns for some parents. 'That's another terrifying piece,' said Ebony Turner, a lawyer and former Democratic candidate for local office whose son has Down syndrome. Speaking from her office in Mansfield, Texas, she added, 'This is a slippery slope.' Andrew Nixon, a spokesman for the Department of Health and Human Services, said in a statement that 'Secretary Kennedy is not anti-vaccine — he is pro-safety, pro-transparency and pro-accountability.' 'Claims that Secretary Kennedy is spreading misinformation or undermining vaccine confidence are flat-out false,' he said. 'Secretary Kennedy's leadership is grounded in a relentless commitment to improving the health of our nation — especially for children.' Mr. Kennedy has a devoted following. Wellness influencers and other 'MAHA moms' promote him in a social media ecosystem that Democrats and MAHA critics are struggling to match. 'Democrats are absolutely awful at communication,' said Jessica Knurick, a dietitian with a Ph.D. in nutrition science who said she used her substantial online presence to try to 'break through with accurate information, no matter what side it's coming from politically.' She added, 'In the science and medical space, we have a messaging problem.' In interviews around the country, numerous voters said they had not closely followed Mr. Kennedy's comments. Others saw no contradiction in both supporting Mr. Trump's administration and embracing vaccines — a perspective many doctors welcome as they stress that public health issues should not be political. But voters' ability to hold both views suggests that concerns about the Trump administration's stewardship of public health are not guaranteed to prompt electoral backlash. 'Something that Democrats need to be doing a better job at is how we can elevate issues and highlight individual stories and make it real for people,' Ms. Pettersen said. Some Democrats argue that their efforts to sound alarm bells on public health are beginning to work, with congressional Republicans agonizing over their push to cut Medicaid spending. 'Tell your billionaire friends they can only have one yacht' Mallory McMorrow, a Democratic state senator in Michigan running for U.S. Senate, was at her 4-year-old's swim class recently, talking with a fellow mom who had one child. 'I asked if she was considering having another one, and she said, 'Not if things keep up like this,'' Ms. McMorrow said in an interview, referring to rising child-related costs. 'There's a lot of anxiety for parents.' Mr. Trump's allies hope that parents reach different conclusions. The White House has heard out ideas for persuading Americans to have more children; one proposal is a $5,000 'baby bonus.' Mr. Trump also signed an executive order reaffirming his commitment to lowering the costs of in vitro fertilization. 'President Trump has always prioritized the well-being of our nation's families,' Kush Desai, a White House spokesman, said in a statement. He pointed to efforts to review baby formula and said Mr. Trump's economic agenda was aimed at 'rebuilding communities that have been hollowed out by decades of 'free' trade deals so that working-class families can once again thrive.' But Mr. Trump has acknowledged that his tariff policies may have consequences even for kids. 'Maybe the children will have two dolls instead of 30 dolls,' he said recently. To Democrats, it was an outrageous statement, and an opening to cast the administration as out of touch. 'Parents are just supposed to sit here and take parenting advice from President Trump,' said Representative Hillary Scholten, a Michigan Democrat, incredulously. 'When it comes to, you know, the tax code, parents are going to be telling him, 'Tell your billionaire friends they can only have one yacht.'' Senator Ruben Gallego, an Arizona Democrat who is expecting a third child in June, has called Mr. Trump's tariffs a 'baby tax' and declared that the administration is 'anti-baby,' given the rising costs of strollers and car seats. He expressed confidence that voters would respond. 'They're going to get it,' he said. 'They're going to understand that: 'Last year, my cousin, you know, had a baby, and things weren't as expensive. And now they are expensive.'' In an interview, Mr. Gallego showed another way that the subject of children could be politically useful: to deflect questions about a presidential campaign. Asked if anything about a 2028 bid might appeal to him, Mr. Gallego, who has been amping up his national profile, replied, 'By that point, I'd have three little babies, and so focusing on being a good dad and a good senator is the only thing that's appealing to me right now.'
Associated Press
28-04-2025
- Health
- Associated Press
Mirror Biologics Announces Publication of Clinical Results Showing Potential for Allo-Priming to Provide Broad Protection to Elderly from Respiratory Viral Infection
Wesley Chapel, FL April 28, 2025 --( )-- Mirror Biologics, Inc today announces publication in the journal Vaccines the results of a clinical trial designed to test the ability of the experimental drug called AlloStim® to modulate the immune system of the elderly in such a manner that the elderly might respond to a viral infection in the same manner as a younger person responds. This type of vaccine protocol is called 'Allo-Priming' and was previously proposed as a possible ' Universal Vaccine ' against respiratory viral infection in the elderly. The elderly population is at increased risk for severe disease from viral infections, especially viruses circulating in the community such as common cold viruses, the flu (influenza), COVID-19 and respiratory syncytial virus (RSV) leading to hospitalization. With the aging population, the rates of hospitalization for severe disease from respiratory viral infections are rising. It has been reported that pneumonia is the third most common reason for hospitalization for persons aged 65 years and a major cause of death. The increased incidence of hospitalization in the elderly due to viral infections also has significant repercussions for public health systems and on healthcare costs. Vaccination programs are designed to help protect against severe disease from some common respiratory viral infections, however the elderly often do not respond well to these vaccines and remain vulnerable to infection, especially those living in assisted living environments. Nursing home-acquired pneumonia occurs in an estimated 1-2 patients for every 1000 days of nursing home residence. Nursing home residents diagnosed with pneumonia and requiring hospitalization have reported mortality ranging from 13 to 41%. The COVID-19 pandemic highlighted the scale of global unpreparedness to deal with the fast-arising needs of global health threats, causing untold fear and suffering for older people across the world. In addition, this recent pandemic highlighted the problems with attempting to vaccinate against a virus with the capability of rapidly changing its antigenic identity. Dr. Michael Har-Noy, Chief Medical Officer at Mirror Biologics and corresponding author of the publication stated: 'In this clinical study, Mirror's scientists and clinical collaborators are addressing the problem of how to protect the elderly from the adverse effects of both known and future unknown viral threats, including a future virus with pandemic potential. The clinical results support the potential of our novel approach to modulate the immune system of the elderly in order to reset to be like a new young immune system that is capable of learning to protect showed great potential. Healthy adults over 65 years old were found to have acquired protection against common respiratory viruses that amplified over time, even though no viral antigens were incorporated in the formulation. We are now seeking a partner to assist us to complete the clinical testing necessary to make this experimental approach available to those in need.' The results of this clinical trial suggest the Allo-Priming might provide the elderly with broad protection against severe disease from any type of respiratory viral infection, including common viruses and mutations, as well as protection from a future unknown pandemic virus without the need for prior knowledge of the type of virus and without the need for annual booster shots. About Mirror Biologics Mirror Biologics, Inc. is a private Delaware corporation with headquarters in Tampa, Florida. Mirror also has GMP manufacturing operations in Jerusalem, Israel and additional clinical operations in Thailand and Malaysia. The lead product candidate, AlloStim® is an 'off-the-shelf' non-genetically manipulated, living, immune cell immunotherapy protected by over 200 issued patents worldwide and derived from precursors purified from the blood of healthy donors. AlloStim® is a platform drug, that is broadly applicable to cancer and infectious disease indications. AlloStim® is being evaluated in clinical trials as a possible treatment for metastatic colorectal cancer and advanced liver cancer. Contact Information: Mirror Biologics, Inc. Thu Bui 619-227-4872 Contact via Email Read the full story here: Mirror Biologics Announces Publication of Clinical Results Showing Potential for Allo-Priming to Provide Broad Protection to Elderly from Respiratory Viral Infection Press Release Distributed by
Associated Press
16-04-2025
- Health
- Associated Press
GeoVax Highlights New Study Demonstrating the Strength of Multi-Antigen COVID-19 Vaccine Candidates
Peer-Reviewed Data Reinforces GeoVax's Multi-Antigen Strategy With GEO-CM02 and Supports Advancement of GEO-CM04S1 Clinical Programs ATLANTA, GA - April 16, 2025 ( NEWMEDIAWIRE ) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, today announced the publication of a peer-reviewed article in Vaccines (MDPI) titled ' Preclinical Evaluation of a Multi-Antigen SARS-CoV-2 Vaccine Candidate GEO-CM02.' The study provides compelling preclinical evidence of the benefits of GeoVax's multi-antigen COVID-19 vaccine approach, utilizing the well-recognized MVA (Modified Vaccinia Ankara) platform. The findings further validate the approach taken by GeoVax with its lead clinical candidate, GEO-CM04S1, currently being evaluated in multiple Phase 2 clinical trials, especially focused on addressing the current unmet COVID-19 vaccine needs of immunocompromised populations. Dr. Mukesh Kumar, lead author and Associate Professor at Georgia State University, stated: 'We are excited to share these compelling results based upon our collaboration with GeoVax. This study highlights the potential of multi-antigen vaccines to overcome the limitations of first-generation, spike-only vaccines. GeoVax's GEO-CM02 vaccine demonstrates promising protection against SARS-CoV-2 variants, offering a strategy that may sustain vaccine effectiveness as the virus continues to evolve.' The publication supports the rationale for advancing next-generation COVID-19 vaccines capable of delivering broader, more durable immune responses. Notably, the study demonstrated that GEO-CM02 conferred superior protection in animal models against multiple SARS-CoV-2 variants compared to spike-only vaccines. David Dodd, Chairman and CEO of GeoVax, commented: 'GeoVax has an active, advancing clinical program in support of demonstrating the critically important value of GEO-CM04S1, addressing the limitations of first-generation COVID-19 vaccines: (a) more robust immune protection, (b) increased durability, and (c) providing protection to those immunocompromised individuals - over 40 million adults in the U.S. and more than 400 million worldwide - who do not respond adequately to first-generation vaccines. In addition, GEO-CM02 provides encouraging demonstrative data for future multi-antigen COVID-19 vaccines, especially in providing protective immunity against future variants.' These results come at a time when public health leaders are emphasizing the importance of evolving beyond single-antigen vaccine strategies. Last week, U.S. Health and Human Services Secretary Kennedy acknowledged the critical value of multi-antigen vaccines as part of the next phase of pandemic preparedness and biodefense. Dodd added: 'SARS-CoV-2 continues to evolve, and it remains critically important that next-generation COVID-19 vaccines such as GEO-CM04S1 and GEO-CM02 continue to progress. GeoVax remains committed to advancing these programs, including our ongoing clinical studies supporting vulnerable populations who remain underserved by currently approved, single-antigen vaccine options.' GeoVax's GEO-CM04S1 is currently being evaluated in three clinical trials, including a completed trial among healthy volunteers and ongoing studies focused on patients with chronic lymphocytic leukemia (CLL) and other blood cancers. Interim data from the CLL study have demonstrated promising safety and immunogenicity, further supporting the role of this candidate in broadening protection against COVID-19. About GeoVax GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin(R), having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The Company is also developing GEO-MVA, a vaccine targeting Mpox and smallpox. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: Forward-Looking Statements This release contains forward-looking statements regarding GeoVax's business plans. The words 'believe,' 'look forward to,' 'may,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'should,' 'plan,' 'could,' 'target,' 'potential,' 'is likely,' 'will,' 'expect' and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax's immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax's viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax's immuno-oncology products and preventative vaccines will be safe for human use, GeoVax's vaccines will effectively prevent targeted infections in humans, GeoVax's immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Company Contact: [email protected] 678-384-7220 Investor Relations Contact: [email protected] 212-698-8696
